Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1746

1.

The economics of pediatric formulation development for off-patent drugs.

Milne CP, Bruss JB.

Clin Ther. 2008 Nov;30(11):2133-45. doi: 10.1016/j.clinthera.2008.11.019. Review.

PMID:
19108801
2.

Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.

Giacoia GP, Taylor-Zapata P, Mattison D.

Clin Ther. 2008 Nov;30(11):2097-101. doi: 10.1016/j.clinthera.2008.11.017.

PMID:
19108797
3.
4.

European perspectives on pediatric formulations.

Breitkreutz J.

Clin Ther. 2008 Nov;30(11):2146-54. doi: 10.1016/j.clinthera.2008.11.016.

PMID:
19108802
5.

Extemporaneous drug formulations.

Nahata MC, Allen LV Jr.

Clin Ther. 2008 Nov;30(11):2112-9. doi: 10.1016/j.clinthera.2008.11.020. Review.

PMID:
19108799
6.

Newborns and drug studies: the NICHD/FDA newborn drug development initiative.

Giacoia GP, Mattison DR.

Clin Ther. 2005 Jun;27(6):796-813.

PMID:
16117987
7.

What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?

Dionisio D, Gass R, McDermott P, Racalbuto V, Madeo M, Braghieri G, Crowley S, Pinheiro Edos S, Graaff P, Vasan A, Eksaengsri A, Moller H, Khanna AK, Kraisintu K, Juneja S, Nicolaou S, Sengupta A, Esperti F, Messeri D.

Curr HIV Res. 2007 Mar;5(2):155-87.

PMID:
17346132
8.

Criteria supporting the study of drugs in the newborn.

Ward RM, Benitz WE, Benjamin DK Jr, Blackmon L, Giacoia GP, Hudak M, Lasky T, Rodriguez W, Selen A.

Clin Ther. 2006 Sep;28(9):1385-98. Review.

PMID:
17062311
9.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

10.

How to anticipate the assessment of the public health benefit of new medicines?

Massol J, Puech A, Boissel JP; Participants inRound Table No 7, Giens XXII..

Therapie. 2007 Sep-Oct;62(5):427-35. doi: 10.2515/therapie:2007071.

PMID:
18206104
11.

Unlicensed and off-label drug use: issues and recommendations.

Conroy S.

Paediatr Drugs. 2002;4(6):353-9.

PMID:
12038871
12.

Integration of pediatric aspects into the general drug development process.

Rose K.

Ernst Schering Res Found Workshop. 2007;(59):123-34. Review.

PMID:
17117719
14.

Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.

Giacoia GP, Mattison DR.

Clin Ther. 2006 Sep;28(9):1337-41. Review.

PMID:
17062307
15.

Clinical trials in pediatrics: The drug delivery dimension.

Osuntokun B.

Adv Drug Deliv Rev. 2006 Apr 20;58(1):90-105. Review.

PMID:
16529842
16.

Pediatric research: coming of age in the new millennium.

Milne CP.

Am J Ther. 1999 Sep;6(5):263-82. Review.

PMID:
11329108
17.

Public-private partnership models in France and in Europe.

Demotes-Mainard J, Canet E, Segard L.

Therapie. 2006 Jul-Aug;61(4):325-34, 313-23. Review. English, French.

PMID:
17124948
18.

Children on losing end of access to new drugs.

[No authors listed]

AIDS Alert. 1998 Jan;13(1):10-2.

PMID:
11364862
19.

Economics and structure of the generic pharmaceutical industry.

Kirking DM, Ascione FJ, Gaither CA, Welage LS.

J Am Pharm Assoc (Wash). 2001 Jul-Aug;41(4):578-84. Review.

PMID:
11486984
20.

Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.

Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G.

Eur J Clin Pharmacol. 2002 Nov;58(8):495-500.

PMID:
12451425
Items per page

Supplemental Content

Support Center